6 years and older: For immediate-release tablets, 40 mg/day PO for ADHD (doses up to 60 mg/day PO have been used for weight greater than 50 kg) or 60 mg/day PO for narcolepsy. For Adderall extended-release XR capsules, 30 mg/day PO for ADHD. Safety and efficacy have not been established for Mydayis extended-release capsules.3 to 5 years: The maximum dosage is not provided by FDA-approved labeling; Doses should not exceed 40 mg/day PO for immediate-release tablets. Do not use extended-release capsules. Less than 3 years: Safety and efficacy have not been established. Amphetamine; Dextroamphetamine is contraindicated in patients who have received MAOI therapy, including intravenous linezolid or methylene blue, within the past 14 days. MAOI antidepressants slow down amphetamine metabolism and enhance their effect on the release of noradrenaline and other monoamines by adrenergic nerve endings. This can trigger hypertensive seizures, malignant hyperthermia, serotonin syndrome and a variety of toxic neurological effects; These events can be fatal. An increased risk of serotonin syndrome may also occur when amphetamines are administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans and others), and may also occur in overdose situations. In case of serotonin syndrome, discontinue amphetamine; Dextroamphetamine and all other serotonergic agents and initiate supportive therapy.
2.5 mg PO once daily in the morning. May titrate the daily dose in 2.5 mg increments at weekly intervals to the minimum effective dose. The daily dose may be given in 1 to 3 divided doses, 4 to 6 hours apart. Maximum dosage information is not available; However, doses should not exceed 40 mg/day, the usual maximum recommended dose for children aged 6 to 12 years. Although this prescribing information is available on the FDA-approved package label, the American Academy of Pediatrics (AAP) does not recommend the use of amphetamine; Dextroamphetamine in this age group due to lack of safety and efficacy data. Doctors usually start a dose of Adderall with the smallest amount that can potentially work, and then gradually increase it. For ADHD, the immediate-release dosage for adults ranges from 5 mg to 40 mg per day. The dosage is spread throughout the day. In terms of ADHD, doses above 40 mg per day are rarely more effective than smaller amounts. For the treatment of narcolepsy, doctors can start with 5 mg per day, then go up to 60 mg per day, with doses administered every four to six hours.
Adderall XR takes one dose daily instead of split doses. A doctor may still recommend that the extended-release dose not exceed 40 mg per day. Amphetamine; Dextroamphetamine is contraindicated in patients with symptomatic heart disease, advanced atherosclerosis and moderate to severe hypertension. The FDA recommends that stimulants generally not be used in patients with known serious cardiac structural abnormalities, acute myocardial infarction, aortic stenosis, prosthetic valves, valve valves, cardiomyopathy, ventricular dysfunction or heart failure, arrhythmias, coronary artery disease, or other serious heart problems. Stimulant medications can increase blood pressure or heart rate in some people; More serious cardiac effects have also been associated with stimulant use. Sudden unexplained death (SUD) and myocardial infarction have occurred in adults receiving standard-dose stimulants for attention deficit hyperactivity disorder (ADHD). Sudden death has also been associated with stimulant drugs at doses usual in pediatrics with structural heart abnormalities or other serious heart problems. A large retrospective cohort study of over 1.2 million children and young adults aged 2 to 24 years found no increased risk of serious cardiovascular events in current users of ADHD medications compared to non-users (adjusted hazard ratio 0.75; 95% CI 0.31 to 1.85). Similar results were seen when current ADHD medication users were compared to former users and when current users with severe underlying cardiovascular disease were included in the analysis. The authors concluded that, although the absolute magnitude of risk appears small, a moderate increase in risk cannot be excluded.
The American Heart Association (AHA) states that it is reasonable to consider the use of these drugs in pediatric patients with congenital heart defects without current hemodynamic or arrhythmic concerns or congenital heart defects considered stable by the patient`s pediatric cardiologist, unless the cardiologist has specific concerns. However, these patients should be closely monitored and discontinuation of treatment should be considered if the patient develops any of the following conditions: heart disease associated with sudden cardiac death (SCD), arrhythmia requiring cardiopulmonary resuscitation, direct current cardioversion/defibrillation or overexertion stimulation, arrhythmia associated with sickle cell disease, clinically significant arrhythmia that is not treated or controlled, QTc on electrocardiogram (ECG) more than 0.46 sec. or heart rate or blood pressure more than 2 SD higher than the mean value for age. All patients considered for treatment with stimulant drugs should have a careful medical history, including an assessment of a family history of sudden death or ventricular arrhythmias and a physical examination to assess the presence of heart disease. If heart disease is suspected, a more thorough cardiac examination, including ECG and echocardiogram, is warranted. For pediatric patients, the AHA states that it makes sense to get a baseline ECG as part of the initial assessment. If a child or teen has significant results on physical exam, ECG, or family history, consult a pediatric cardiologist before starting stimulant medications. Once the medication has started, a repeated ECG may be helpful if the original ECG was obtained before the child was 12 years old, if heart symptoms develop, or if the family history changes. When you look at the dosage of Adderall, there are differences between extended-release and immediate-release options. Adderall dosing instructions are different for both. Immediate-release products: There are no specific guidelines for dose adjustments of immediate-release products for renal impairment in adults and pediatric patients.
FDA-approved product labeling indicates that renal dysfunction inhibits amphetamine elimination and can lead to prolonged exposure; Be careful. RENIEREN DOSE ADJUSTMENTS FOR ADULTSrenal dose adjustments for extended-release capsules (Adderall XR)eGFR 15 to 29 ml/minute/1.73 m2: 15 mg PO once daily in the morning. eGFR less than 15 ml/minute/1.73 m2: The introduction of extended-release capsules (Adderall XR) is not recommended. Renal dose adjustments for adults for extended-release capsules (Mydayis)eGFR 15 to 29 ml/minute/1.73 m2: The starting dose is 12.5 mg PO once daily. The maximum dose is 25 mg, eGFR less than 15 ml/minute/1.73 m2: The introduction of extended-release capsules (Mydayis) is not recommended. PAEDIATRIC RENAL DOSE ADJUSTMENTSPAEDIATRIC renal dose adjustments (6 to 17 years) for extended-release capsules (Adderall XR)eGFR 15 to 29 ml/minute/1.73 m2: 5 mg PO once daily is the recommended dose. The maximum dose for children aged 6 to 12 years is 20 mg PO once daily. eGFR less than 15 ml/minute/1.73 m2: Initiation of extended-release capsules (Adderall XR) is not recommended. Paediatric renal dose adjustments (13 to 17 years) for extended-release capsules (Mydayis)eGFR 15 to 29 ml/minute/1.73 m2: The initial and maximum dose is 12.5 mg PO daily. eGFR less than 15 ml/minute/1.73 m2: The introduction of extended-release capsules (Mydayis) is not recommended.
Use amphetamines; Dextroamphetamine with caution in patients with a history of seizure disorders, as the seizure threshold may be reduced, especially with excessive CNS stimulation (i.e. amphetamine overdose). The effects of amphetamines on the seizure threshold are less clear at normal therapeutic doses. The seizure threshold may be lowered in patients with EEG abnormalities and rarely in patients without a history of epilepsy or EEG abnormalities. If seizures occur, discontinuation of treatment is recommended. Children as young as 3 years old have been successfully treated with amphetamines for attention deficit hyperactivity disorder (ADHD). It should be noted that not all children with ADHD need medication; Non-drug measures are often initiated at the same time as drug therapy. Amphetamines are not recommended in children and infants under 3 years of ageThe effectiveness of stimulant therapy in children with ADHD is supported by a large amount of evidence. However, do not use the Mydayis extended-release capsule formulation in children under 13 years of age, as safety and efficacy have not been established and a higher rate of side effects has been found in clinical trials with this formulation than in adolescents.